Genitourinary Syndrome of Menopause (GSM)

Genitourinary syndrome of menopause (GSM) is the modern medical term for what used to be called 'vaginal atrophy' or 'atrophic vaginitis' — and the new name matters because the condition affects the whole genitourinary tract, not just the vagina. In short: if you have vaginal dryness, discomfort or pain with intimacy, or urinary urgency and repeat infections, safe and effective treatments exist. You do not have to accept it as 'just part of getting older'. Below is what GSM is, how common it is, and what works best.

What is GSM and why does the name matter?

The vagina, vulva, urethra and bladder all carry oestrogen receptors, and after menopause falling oestrogen changes the tissues and the microbiome across this entire area. That is why symptoms can include dryness and burning, discomfort or pain during sex, urinary urgency and recurrent urinary tract infections. Because several structures are involved, symptoms differ from woman to woman and often build gradually rather than appearing overnight. It is a common medical condition — not a hygiene issue and not something to be embarrassed about.

How falling oestrogen changes the tissue:

The lining of the vagina is not a fixed surface. It is tissue that renews itself, and oestrogen is the signal that keeps the renewal going. Its cells hold water, produce glycogen, and shed and replace themselves on a regular cycle. Blood flow to the area is good, and the surface stays plump, lubricated and slightly acidic.

When oestrogen falls, each of those properties changes. The tissue becomes thinner and less elastic. Less glycogen means less of the acidity that keeps the local environment balanced, so the mix of bacteria shifts — which is why infections become easier to catch and harder to shift. Natural lubrication falls. Blood flow drops. The surface becomes drier, more fragile, and slower to repair itself after any small injury.

None of this is a matter of hygiene, and none of it is caused by anything you did. It is the same loss of oestrogen that affects bone and blood vessels, showing up in a tissue that is especially sensitive to it.

Why the bladder is involved at all:

Many women are puzzled that a vaginal problem produces urinary symptoms. The explanation is that the two are not separate.

The lower urinary tract — the urethra, the bladder neck, and the tissue supporting them — responds to oestrogen in the same way as the vagina, and shares much of the same tissue. When oestrogen falls, the urethral lining thins, the seal at the bladder neck becomes less reliable, and the surrounding support weakens. That combination produces urgency, frequency, and a greater tendency to infection.

This is why treating only the vagina can leave the urinary symptoms untouched, and why low-dose vaginal oestrogen often improves both: applied locally, it reaches the shared tissue. It is also why repeated urinary infections after menopause should prompt a conversation about GSM, rather than another course of antibiotics and nothing else. Infection that keeps returning with no structural cause is a pattern worth looking at as a whole.

How common is GSM?

GSM affects roughly half of postmenopausal women. Yet fewer than 25% of those affected ever mention it to a doctor, usually out of embarrassment or the mistaken belief that nothing can help. In reality, a great deal can be done, and the first step is simply an open conversation. If you recognise these symptoms in yourself, you are not alone — and it is nobody's fault.

What the latest research shows (2026):

A systematic review in Maturitas, covering 23 studies and 5,027 participants, confirmed that the postmenopausal microbiome is marked by reduced Lactobacillus and greater microbial diversity. In the SWAN cohort (1,320 women), sexual pain was independently linked to a specific microbiome profile (CST IV-C1; OR 2.26, 95% CI 1.20-4.23). Certain bacteria tracked with particular symptoms: Prevotella with urinary symptoms, Finegoldia magna with recurrent urinary infections and Streptococcus with sexual pain. The parallel loss of lactobacilli across the vagina, urine and gut points to a vaginal-bladder-gut axis, possibly through disruption of the so-called 'estrobolome'. Notably, oestrogen therapy partly restored lactobacillus dominance but did not uniformly improve symptoms — a sign that restoring the microbiome alone does not predict symptom relief and that treatment needs to be considered as a whole.

What else causes dryness and urinary symptoms:

Dryness and urinary symptoms are not automatically GSM, and a few other explanations are common enough to be worth knowing.

• Irritants — scented washes, douches, fabric conditioners, some laundry products — which cause soreness that eases when the product stops
• Thrush and other infections, which usually bring discharge, itching or an odour, and come and go rather than building steadily
• Skin conditions affecting the vulva, such as eczema and lichen sclerosus, which cause patches, itching or a change in how the skin looks
• Some medicines, which can dry the body's secretions as a side effect
• A urinary infection, which causes burning and urgency that arrive suddenly rather than gradually
• Diabetes, which raises the risk of both urinary infection and dryness
• A bladder or pelvic floor problem that has nothing to do with hormones

Several of these can overlap with GSM, so finding one does not always rule out the other.

How GSM is told apart from those causes:

The distinguishing feature of GSM is its direction. It builds gradually, over months, and it does not go back.

An irritation clears when the product stops. An infection improves with treatment and then behaves differently. GSM keeps going, because the oestrogen that maintained the tissue is not coming back on its own.

Other features point the same way. The dryness is present most of the time rather than in episodes. Symptoms tend to affect the vagina, the vulva and the urinary tract together rather than one alone. There is no discharge with an unusual smell. And the symptoms sit alongside other changes of the transition — the same women often have flushes, disturbed sleep, or a cycle that has changed or stopped.

What makes GSM easy to miss is that women rarely volunteer it and doctors rarely ask. Symptoms present for a long time come to feel normal, and the expectation that ageing simply means discomfort does the rest.

What does The Menopause Society recommend?

• Low-dose vaginal oestrogen (cream, tablet or ring) is the first-line treatment; absorption into the bloodstream is minimal, it is very safe, and applied locally to the vulva and vagina it relieves dryness and sexual pain
• Ospemifene, an oral SERM, is approved for GSM and offers an option for women who prefer a pill
• Vaginal moisturisers used 2-3 times a week keep the tissues comfortable and may be enough for mild symptoms
• Water- or silicone-based lubricants used during sex reduce friction and discomfort
• Regular sexual activity after menopause stimulates blood flow and keeps vaginal tissue healthy
• Postmenopausal women are more vulnerable to sexually transmitted infections because fragile vulvar tissues let viruses in more easily

What to remember about treatment:

GSM is chronic — symptoms return if treatment stops, so treatment does not 'cure' it permanently but keeps symptoms under control while it is used. Vaginal oestrogen has the best evidence-to-risk ratio of any menopause treatment and is considered safe for most breast cancer survivors after discussion with their oncologist. If symptoms are affecting your sleep, relationships or quality of life, you deserve help: raise the topic openly with your doctor.

What to say when you raise GSM:

• Say it plainly, early in the appointment. 'I have pain with sex' or 'I keep getting urinary infections' is enough to open the conversation — you do not need the medical term.
• Say when it started and whether it is getting worse.
• Say which situations it affects: sex, walking, sitting, exercise, using the toilet.
• Say what you have already tried, including anything from a pharmacy, and whether it helped.
• Say how it is affecting your relationship, your sleep or your mood, if it is.
• Ask directly whether low-dose vaginal oestrogen is suitable for you, or whether something else fits your history better.

Naming the practical detail is what moves the conversation forward. 'It is sore' can be answered with sympathy alone; 'it is sore for two days after sex and it has been getting worse since the spring' cannot.

Questions worth asking about treatment:

• Which option suits me, and why?
• How long before I notice a difference?
• Do I need to keep using it indefinitely, or will it be reassessed?
• Are there reasons a particular option would not be suitable in my situation?
• What should I do if symptoms return after they improve?
• Is there anything I should avoid — washes, douches, scented products?
• Do I also need a lubricant or a moisturiser, and how do the two differ?

That last distinction is often the missing piece at home. A lubricant is used at the time of sex to reduce friction. A moisturiser is used regularly, whether or not you are sexually active, to keep the tissue comfortable day to day. They do different jobs, and many women benefit from both.

Settled questions and open questions in GSM:

Some of this is settled. That falling oestrogen causes these tissue changes is not in dispute. That low-dose vaginal oestrogen relieves dryness and pain with sex, with very little absorbed into the bloodstream, is well established, and it remains the first-line treatment.

What is still being worked out is the microbiome. The research described above shows a clear shift away from lactobacilli after menopause, and a link between certain bacterial profiles and particular symptoms. But restoring the bacteria has not reliably restored comfort. The honest position is that the microbiome is part of the picture and not yet a treatment target in itself.

There is also an open question about matching. The options are known to work; deciding which woman does best with which one is still a matter of clinical judgement, and of what she is willing to use consistently.

Why 'it's just ageing' keeps women silent:

• 'It is just part of getting older.' It is a treatable condition with a name, not an inevitable consequence of age.
• 'It is not serious enough to mention.' It affects sleep, relationships and quality of life. That is reason enough.
• 'My doctor will be embarrassed.' Most clinicians would far rather be asked than have a treatable problem go unmentioned. If it feels awkward with one, that is a reason to ask another — not a reason to stay silent.
• 'It means I am no longer interested in sex.' Dryness is a tissue problem, not a statement about desire. Treating it often changes the picture entirely.
• 'Nothing can be done at my age.' A great deal can. The treatments that work are simple and well established.
• 'It will settle down on its own.' It does not. Left alone, it tends to build gradually.

In short:

GSM affects about half of postmenopausal women and shows up as dryness, discomfort with intimacy, urinary urgency and recurrent infections. It is chronic but responds very well to treatment, with low-dose vaginal oestrogen as a safe and effective first line. You do not need to suffer in silence — treatment exists and it works.